Oncoinvent ASA: New share capital registered

10 Dec 2025 18:15 CET

10 December 2025: Reference is made to the stock exchange announcements
published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,
and subsequent announcements, regarding the contemplated fully underwritten
rights issue of 260,000,000 new shares in the Company (the "Offer Shares")
raising gross proceeds of NOK 130 million (the "Rights Issue"). Further,
reference is made to the stock exchange announcement published by the Company on
5 December 2025 regarding the resolution by the board of directors of the
Company to issue 31,199,997 new shares in the Company, each with a nominal value
of NOK 0.50, at a subscription price of NOK 0.50 per share (the "Underwriting
Commission Shares") to be delivered to the underwriters pursuant to the
subscription and underwriting agreements dated 30 June 2025 as settlement of
their entitlement to an underwriting fee under said agreements.

The share capital reduction to reduce the nominal value of the shares in the
Company and the share capital increases pertaining to the issuance of the Offer
Shares and the Underwriting Commission Shares have today been registered with
the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital following the share capital reduction and
the share capital increases related to the issue of the Offer Shares and the
Underwriting Commission Shares is NOK 223,920,562.50 divided into 447,841,125
shares, each with a nominal value of NOK 0.50.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases in the peritoneum post-surgery, harnessing the benefits of
modern radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial in ovarian cancer is
currently ongoing in the US and Europe. Early clinical efficacy data are highly
encouraging, and no serious toxicity or safety concerns have been reported to
date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug
products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo
Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly
target microscopic metastases in the abdominal cavity following surgery.
Radspherin® is currently in development as a post-surgical treatment for
patients with cancer that has spread to the abdominal cavity - a group with very
limited treatment options today. The drug candidate offers a distinctly unique
therapeutic approach with several differentiating features, including the use of
radium-224, single-dose treatment with a sustained therapeutic effect, non
-systemic administration, direct targeting and an exceptional dose-to-tumor
ratio, maximizing efficacy while limiting harm to healthy tissue.

More information:
Access the news on Oslo Bors NewsWeb site